Active, Not Recruiting
A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
NCT03835819
- Conditions
- Endometrial Cancer, Endometrial Neoplasms, Female Urogenital Diseases, +10 more
- Locations
-
- Dana Farber Cancer Institute Boston, Massachusetts, United States
- University of Massachusetts Worcester, Massachusetts, United States
- Northwell Cancer Institute Lake Success, New York, United States